Literature DB >> 10719066

NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117.

M Nakai1, Z Qin, Y Wang, T N Chase.   

Abstract

The excitotoxic response of striatal neurons to NMDA and non-NMDA receptor agonists involves the nuclear translocation of transcription factor nuclear factor-kappa B (NF-kappaB) due to IkappaB-alpha degradation. Resultant augmentation in c-Myc, p53 and cyclin D1 expression presages the apoptotic-like destruction of these cells in vivo. To differentiate molecular events triggered by intrastriatally injected quinolinic acid (QA, 60 nmol) and kainic acid (KA, 2.5 nmol), we compared the effects of a caspase-3 inhibitor (DEVD.CHO, 8 microgram intrastriatally), a free radical scavenger (OPC-14117; 600 mg/kg, orally) and ethanol (2.14-8.6 micromol, intrastriatally or 25-100 mmol/kg, orally) on changes induced by these glutamatergic agonists on NF-kappaB cascade components and the apoptotic death of rat striatal neurons in vivo. The results indicated that the QA-induced degradation of IkappaB-alpha is almost totally mediated by a caspase-3-dependent mechanism, while KA-induced IkappaB-alpha degradation is only partially dependent on caspase-3. OPC-14117 attenuated the effects of QA but not KA on IkappaB-alpha degradation, suggesting that oxidative stress contributes to the QA- but not the KA-induced degradation of IkappaB-alpha. In contrast, ethanol inhibited the KA- but not the QA-induced degradation of IkappaB-alpha and the ensuing DNA fragmentation and loss of striatal GABAergic neurons. It would now appear that NF-kappaB activation in striatal neurons induced by NMDA or KA receptor stimulation involves different biochemical mechanisms. Since excitotoxicity associated with NF-kappaB activation may contribute to neuronal degenerative disorders such as Huntington's disease, a more detailed understanding of biochemical events underlying ionotrophic glutamate receptor-stimulated cell death may assist in the discovery of alternative approaches to interdicting the deleterious consequences of excitotoxic insult.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719066     DOI: 10.1016/s0006-8993(00)01959-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Ameliorating effects of Kangen-karyu on neuronal damage in rats subjected to repeated cerebral ischemia.

Authors:  Fengling Pu; Tomohiro Kaneko; Makiko Enoki; Keiichi Irie; Takuya Okamoto; Yasuo Sei; Nobuaki Egashira; Ryozo Oishi; Kenichi Mishima; Hidetoshi Kamimura; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  J Nat Med       Date:  2010-02-13       Impact factor: 2.343

2.  NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase.

Authors:  A S Mandir; M F Poitras; A R Berliner; W J Herring; D B Guastella; A Feldman; G G Poirier; Z Q Wang; T M Dawson; V L Dawson
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

Review 3.  Role of p53 in neurodegenerative diseases.

Authors:  J Robert Chang; Mohammad Ghafouri; Ruma Mukerjee; Asen Bagashev; Tinatin Chabrashvili; Bassel E Sawaya
Journal:  Neurodegener Dis       Date:  2011-10-28       Impact factor: 2.977

Review 4.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

5.  Cathepsin L plays a role in quinolinic acid-induced NF-Κb activation and excitotoxicity in rat striatal neurons.

Authors:  Yan-Ru Wang; Shu Qin; Rong Han; Jun-Chao Wu; Zhong-Qin Liang; Zheng-Hong Qin; Yan Wang
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

6.  Biphasic activation of nuclear factor-kappa B in experimental models of subarachnoid hemorrhage in vivo and in vitro.

Authors:  Wan-Chun You; Wei Li; Zong Zhuang; Yong Tang; Hu-Chen Lu; Xiang-Jun Ji; Wei Shen; Ji-Xin Shi; Meng-Liang Zhou
Journal:  Mediators Inflamm       Date:  2012-09-23       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.